Review

RNA biology at the crossroads of genomics, epigenetics, and medicine

Prasoon Kumar Thakur 1*

1 Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague 4 Czech Republic.

* Correspondence: prasoon-kumar.thakur@img.cas.cz (P.K.T.)

Citation: Thakur, P.K. RNA biology at the Crossroads of genomics, epigenetics, and medicine. Glob. Jour. Bas. Sci. 2025, 2(1). 1-8.

Received: August 29, 2025

Revised: October 21, 2025

Accepted: November 07, 2025

Published: November 13, 2025

doi: 10.63454/jbs20000068

ISSN: 3049-3315

Volume 2; Issue 1

Download PDF file

Abstract: Ribonucleic acid (RNA), once viewed as a mere intermediary between DNA and protein, is now recognized as a central and dynamic player in cellular regulation, forming a critical interface between the genome, the epigenome, and cellular phenotype. This review synthesizes the current understanding of the expansive RNA universe, detailing its diverse species—from coding messenger RNAs (mRNAs) to a vast array of non-coding RNAs (ncRNAs) including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). We explore how RNA biology is deeply integrated with genomic architecture, serving as both a product and a regulator of epigenetic states through mechanisms such as transcription-coupled chromatin remodeling, RNA-directed DNA methylation, and histone modification. Furthermore, we highlight the profound clinical implications of this integration, demonstrating how dysregulated RNA processes contribute to diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions. The advent of high-throughput sequencing and novel therapeutic modalities, including RNA-targeting drugs and mRNA vaccines, underscores RNA’s pivotal role in precision medicine. By examining RNA at this multidisciplinary crossroads, this review elucidates its function as a master regulator and a promising frontier for diagnostic, prognostic, and therapeutic innovation.

Keywords: RNA biology; non-coding RNA; epitranscriptomics; genomics; epigenetics; RNA therapeutics; biomarkers; precision medicine; multi-omics integration

1. Introduction

The classical central dogma of molecular biology, which describes the directional transfer of genetic information from DNA to RNA and ultimately to protein, has long served as a foundational framework for understanding cellular biology. However, this linear view has been profoundly revised over the past two decades as research has revealed the extraordinary complexity and functional diversity of RNA molecules [1]. Rather than functioning merely as a transient intermediary, RNA is now recognized as a central regulatory entity that integrates genomic information with cellular phenotype, environmental cues, and epigenetic regulation. RNA molecules exhibit remarkable structural versatility and functional plasticity, enabling them to act as regulators of transcription, chromatin organization, post-transcriptional gene regulation, and intracellular signaling [1-5]. 

High-throughput sequencing technologies have uncovered that the human genome is pervasively transcribed, producing a vast and heterogeneous transcriptome. Surprisingly, protein-coding exons constitute less than 2% of the total transcriptional output, while the majority of RNA transcripts belong to diverse classes of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar RNAs (snoRNAs), and PIWI-interacting RNAs (piRNAs) [2]. This extensive “RNA world” challenges the traditional protein-centric paradigm and reveals that RNA-based regulatory networks play fundamental roles in orchestrating gene expression programs. These networks decode the static genomic blueprint and dynamically interpret epigenetic signals to regulate cellular differentiation, development, stress responses, and organismal homeostasis.

The integration of RNA biology (Figure 1) with genomics is inherently embedded in molecular biology. Every RNA transcript originates from genomic DNA, and its sequence, structure, splicing pattern, and editing profile are governed by genetic elements such as promoters, enhancers, splice sites, and regulatory motifs. Genetic variation, including single nucleotide polymorphisms (SNPs), structural variants, and copy number alterations, directly influences RNA transcription and processing. Furthermore, RNA molecules provide a functional readout of genome activity, making transcriptomics a critical layer in understanding genotype–phenotype relationships.  Simultaneously, RNA biology intersects deeply with epigenetics, which encompasses heritable changes in gene expression that occur without alterations in the DNA sequence. RNAs actively participate in epigenetic regulation by recruiting chromatin-modifying complexes, guiding DNA methylation machinery, and shaping chromatin architecture. For example, specific lncRNAs function as molecular scaffolds for histone modification complexes, while small RNAs can direct transcriptional gene silencing through RNA-directed DNA methylation pathways [3]. Moreover, RNA molecules contribute to the spatial organization of the genome by facilitating chromatin looping and nuclear compartmentalization. Conversely, epigenetic marks such as DNA methylation and histone modifications determine transcriptional activity and influence RNA biogenesis, stability, and isoform diversity, establishing a bidirectional feedback loop between RNA and epigenetic regulation [6-10].

This convergence of RNA, genomics, and epigenetics has profound and transformative implications for modern medicine. Dysregulation of RNA biogenesis, processing, transport, and degradation is now recognized as a hallmark of numerous diseases. Mutations in RNA-binding proteins, aberrant expression of non-coding RNAs, and disruptions in RNA modification pathways—collectively referred to as epitranscriptomics—have been implicated in cancer, neurodegenerative disorders, cardiovascular diseases, metabolic syndromes, and immune dysfunctions [4]. RNA-based regulatory circuits can act as oncogenic drivers, tumor suppressors, or modulators of disease progression, making them attractive diagnostic biomarkers and therapeutic targets.  

Beyond its role in disease pathogenesis, RNA has emerged as a powerful therapeutic modality. The clinical success of mRNA vaccines during the COVID-19 pandemic demonstrated the feasibility of RNA-based therapeutics at an unprecedented scale. In addition, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and RNA aptamers are being developed to modulate gene expression with high specificity. RNA-guided genome and transcriptome editing technologies, such as CRISPR-Cas systems, further highlight the versatility of RNA as both a biological molecule and a biotechnological tool [5]. These advances underscore the paradigm shift from traditional small-molecule drugs to nucleic acid–based precision therapies. 

In this review, we provide a comprehensive overview of RNA biology at the intersection of genomics,  epigenetics, and medicine. We discuss the genomic origins and functional diversity of RNA species, explore RNA-mediated epigenetic mechanisms, and highlight the emerging roles of RNA in disease diagnosis and therapy. By integrating molecular, genomic, and clinical perspectives, this review positions RNA biology as a central discipline in 21st-century biomedical research and precision medicine.

2. The genomic landscape of RNA transcription

2.1 The complexity of the human transcriptome
The completion of the Human Genome Project and subsequent efforts like ENCODE (Encyclopedia of DNA Elements) revealed the unexpected complexity of genomic output [2, 6]. Far from being a simple collection of isolated protein-coding genes, the genome is a densely packed, overlapping information system. Widespread transcription from both strands produces a staggering array of RNA molecules. This includes not only messenger RNA (mRNA), which is translated into protein, but also a diverse catalog of non-coding RNAs (ncRNAs). These ncRNAs are broadly classified by size and function: small ncRNAs (<200 nt) such as microRNAs (miRNAs), small interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs); and long ncRNAs (>200 nt), including long intergenic non-coding RNAs (lincRNAs), antisense transcripts, and circular RNAs (circRNAs) [7]. This transcriptional complexity allows a finite genome to generate enormous regulatory capacity, with ncRNAs fine-tuning gene expression at virtually every level. 

2.2 Genomic architecture and RNA production
The production and processing of RNA are deeply influenced by genomic architecture. Promoters, enhancers, silencers, and insulators dictate the initiation, rate, and specificity of transcription (Figure 2). Enhancer elements, in particular, can be located hundreds of kilobases from their target promoters and are themselves often transcribed, producing enhancer RNAs (eRNAs) that facilitate chromatin looping and gene activation [8]. Furthermore, the three-dimensional  (3D) organization of the genome within the nucleus, characterized by topologically associating domains (TADs) and chromatin loops, brings distal regulatory elements into proximity, creating transcriptionally active hubs that co-express sets of genes and ncRNAs [9]. This spatial coordination ensures that the genomic blueprint is transcribed in a highly regulated, cell-type-specific manner.

2.3 Alternative splicing and RNA editing
Two key post-transcriptional processes exponentially increase proteomic and functional diversity from a limited set of genes. Alternative splicing, mediated by the spliceosome and regulated by splicing factors, allows a single gene to produce multiple mRNA isoforms with different exon combinations, which can encode distinct protein variants or be subject to nonsense-mediated decay [10]. RNA editing, primarily the deamination of adenosine to inosine (A-to-I) by ADAR enzymes or cytosine to uracil (C-to-U) by APOBEC enzymes, alters the RNA sequence from its genomic template, potentially changing codons, splice sites, or miRNA target sites [11]. Both processes are tightly regulated and their dysregulation is a common feature in disease, highlighting how genomic information is dynamically interpreted at the RNA level.

3. RNA as an epigenetic regulator

3.1 Transcription and chromatin remodeling
The act of transcription itself is a powerful epigenetic event. The passage of RNA polymerase II (Pol II) disrupts nucleosome positioning and recruits chromatin-modifying complexes. For instance, histone methyltransferases like Set1/COMPASS, which deposit the activating H3K4me3 mark, are recruited by the phosphorylated C-terminal domain (CTD) of transcribing Pol II [12]. Thus, transcription elongation directly shapes the local chromatin landscape, creating a memory of recent transcriptional activity that can influence future expression.

3.2 RNA-mediated transcriptional silencing
RNA plays a central role in establishing and maintaining repressive heterochromatin, a fundamental epigenetic state. A canonical example is X-chromosome inactivation (XCI) in female mammals, where the long non-coding RNA Xist is expressed from the future inactive X chromosome (Xi). Xist coats the Xi in cis, recruiting repressive complexes like Polycomb Repressive Complex 2 (PRC2), which catalyzes H3K27 trimethylation, and other modifiers that promote chromatin compaction and transcriptional silencing [13]. Similarly, in many eukaryotes, small interfering RNA (siRNA) pathways guide histone methyltransferases and DNA methyltransferases to homologous DNA sequences to initiate RNA-directed DNA methylation (RdDM) and heterochromatin formation, a key mechanism for silencing transposable elements and maintaining genome stability [14].

3.3 Guiding chromatin-modifying complexes
Beyond heterochromatin, specific lncRNAs act as modular scaffolds or guides to direct chromatin regulators to precise genomic loci. For example, the lncRNA HOTAIR, transcribed from the HOXC cluster, physically interacts with both PRC2 and the LSD1/CoREST/REST complex, recruiting them to the HOXD locus to repress gene expression through coordinated H3K27 methylation and H3K4 demethylation [15]. This paradigm of lncRNAs serving as “address labels” or “tethers” for epigenetic writers, erasers, and readers is now a widely recognized mechanism for the precise spatial control of chromatin states, enabling cell fate decisions and developmental patterning.

4. The epitranscriptome: chemical modifications of RNA

4.1 The diversity of RNA modifications
Analogous to DNA and histones, RNA molecules are chemically modified in a reversible manner, giving rise to the field of epitranscriptomics. Over 170 distinct chemical modifications have been identified on various RNA species, with N6-methyladenosine (m6A) being the most abundant internal modification in eukaryotic mRNA [16]. Other crucial modifications include pseudouridylation (Ψ), 5-methylcytosine (m5C), and N1-methyladenosine (m1A). These modifications are installed by “writer” enzymes (methyltransferases), removed by “eraser” enzymes (demethylases), and recognized by “reader” proteins that interpret the mark to influence RNA fate.

4.2 Functional consequences of m6A and other modifications
m6A serves as a master regulator of post-transcriptional gene expression. It influences nearly every aspect of an mRNA’s lifecycle. Readers like YTHDF proteins can promote mRNA decay or translation, depending on cellular context and co-factors [17]. m6A near stop codons and in 3′ untranslated regions (UTRs) can affect alternative splicing and polyadenylation site choice. Furthermore, m6A is essential for stem cell pluripotency and differentiation, highlighting its role in cell fate decisions [18]. Pseudouridylation alters RNA structure and stability, while modifications on transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) are critical for proper protein synthesis. Dysregulation of the epitranscriptomic machinery is increasingly implicated in cancer and neurodevelopmental disorders, establishing it as a crucial layer of gene regulation at the RNA level. 

5. Clinical implications of RNA biology in human disease

The clinical implications of RNA biology in human disease are profound and transformative, moving from basic science to diagnostics, therapeutics, and personalized medicine (Figure 3). RNA is no longer seen merely as a messenger but as a central player in disease mechanisms and a highly tractable therapeutic target. 

5.1 RNA dysregulation in cancer
Cancer is a disease of dysregulated gene expression, and RNA processes are frequently hijacked. Oncogenic non-coding RNAs are a hallmark: miRNAs like the *miR-17-92* cluster can function as oncogenes (“oncomiRs”) by repressing tumor suppressor genes, while tumor-suppressive miRNAs like *let-7* and *miR-34* are often lost [19]. Similarly, oncogenic lncRNAs such as MALAT1 and H19 promote proliferation, metastasis, and chemoresistance [20]. Mutations in RNA splicing factors (e.g., SF3B1, U2AF1) are recurrent in myelodysplastic syndromes and leukemias, leading to aberrant splicing that can drive oncogenesis [21]. Furthermore, altered m6A dynamics, due to mutations in writers (METTL3, METTL14) or erasers (FTO, ALKBH5), contribute to tumor initiation and progression by affecting the stability of oncogenic transcripts [22].

5.2 Neurodegenerative and neuromuscular disorders
The brain exhibits exceptionally complex RNA metabolism, making it highly vulnerable to RNA-related dysfunction. Many microsatellite expansion disorders, such as myotonic dystrophy (DM1) and fragile X-associated tremor/ataxia syndrome (FXTAS), are caused by expanded CUG or CGG repeats in non-coding regions. These repeats are transcribed into toxic RNA that sequesters essential RNA-binding proteins (e.g., Muscleblind-like proteins in DM1), disrupting global splicing patterns [23]. In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), mutations in RNA-binding proteins like TDP-43 and FUS lead to their cytoplasmic aggregation, loss of normal RNA processing function, and toxic gain-of-function effects [24].

5.3 Cardiovascular and metabolic diseases
RNA biology is also pivotal in cardiovascular health. miRNAs are key regulators of cardiac development, hypertrophy, and fibrosis. For instance, miR-208a, encoded within an intron of the Myh6 gene, is a master regulator of cardiac stress response and a potential therapeutic target for heart failure [25]. In atherosclerosis, endothelial cell dysfunction and inflammation are modulated by specific lncRNAs and miRNAs. In metabolic disorders like diabetes, miRNAs regulate insulin secretion and sensitivity, while RNA modifications influence adipogenesis and energy homeostasis [26].

6. RNA-based diagnostics and therapeutics

6.1 RNA as a diagnostic biomarker
The presence and abundance of specific RNAs in easily accessible biofluids (blood, urine, saliva) offer immense potential for non-invasive diagnostics. Circulating miRNAs show remarkable stability and exhibit disease-specific signatures for cancers, myocardial infarction, and neurological conditions, serving as sensitive biomarkers for early detection, prognosis, and monitoring treatment response [27-41]. Liquid biopsies that profile tumor-derived RNA (including mRNA, miRNA, and fragmented lncRNA) from blood plasma are becoming a reality for cancer management, allowing for dynamic assessment of tumor burden and evolution without invasive tissue sampling [28].

6.2 RNA-targeted therapeutics

The fundamental principle of nucleic acid complementarity—A pairing with T (or U in RNA) and G with C—has been ingeniously leveraged to create a new class of precision medicines that directly target RNA. This represents a paradigm shift from traditional small-molecule drugs, which primarily target proteins, and offers a direct route to address diseases rooted in aberrant gene expression. By rationally designing synthetic nucleic acids with sequences complementary to specific disease-causing RNAs, these therapies can modulate RNA function with exquisite specificity. This field has matured from a promising concept to a clinical reality with multiple approved drugs, each utilizing distinct molecular mechanisms of action [38].

6.2.1 Antisense oligonucleotides (ASOs): Antisense oligonucleotides (ASOs) are chemically modified, single-stranded DNA analogs, typically 15–25 nucleotides in length. Their chemical modifications, such as phosphorothioate backbones and 2′-O-methoxyethyl (2′-MOE) or 2′,4′-constrained ethyl (cEt) ribose modifications, are critical for enhancing nuclease resistance, improving target affinity, and modulating pharmacokinetics [39]. ASOs exert their therapeutic effect through several mechanisms depending on their design and chemistry. The most common mechanism involves recruiting RNase H1, a cellular endonuclease that cleaves the RNA strand of an RNA-DNA heteroduplex. When an ASO binds to its complementary mRNA target, it forms such a duplex, leading to enzymatic degradation of the mRNA and a reduction in the corresponding protein. A second major mechanism is splice modulation. By binding to specific sequences at splice sites or regulatory elements within pre-mRNA, ASOs can sterically block the spliceosome’s access or recruit splicing factors, thereby promoting the inclusion or exclusion of specific exons. This approach is epitomized by Nusinersen (Spinraza®), which binds to a silencer element in the SMN2 pre-mRNA. By blocking this silencer, Nusinersen promotes the inclusion of exon 7, transforming the SMN2 gene—normally a poor backup—into producing functional survival motor neuron (SMN) protein, dramatically altering the course of spinal muscular atrophy (SMA) [29]. Other ASOs function through steric blockade, simply by binding to the 5′ untranslated region (UTR) or start codon of an mRNA to prevent ribosome loading and translation without inducing degradation.

6.2.2 Small interfering RNA (siRNA): Small interfering RNAs (siRNAs) are synthetic double-stranded RNA molecules, typically 21–23 base pairs long, that harness the cell’s endogenous RNA interference (RNAi) pathway. One strand of the siRNA duplex (the guide strand) is loaded into the multi-protein RNA-induced silencing complex (RISC). This complex then uses the guide strand to find and bind perfectly complementary mRNA sequences. The catalytic Argonaute 2 (Ago2) protein within RISC cleaves the target mRNA, leading to its rapid degradation and potent, long-lasting gene silencing [40-41]. The primary challenge for siRNA therapeutics has been efficient delivery to target tissues. A landmark breakthrough was the development of N-acetylgalactosamine (GalNAc) conjugation. By attaching three GalNAc molecules to the siRNA, the drug exploits the asialoglycoprotein receptor, which is highly expressed on hepatocytes, for efficient receptor-mediated endocytosis into the liver. This innovation led to the approval of Patisiran (Onpattro®), an siRNA that silences both mutant and wild-type transthyretin (TTR) mRNA. By reducing the production of misfolded TTR protein that forms toxic aggregates, Patisiran halts the progression of hereditary transthyretin-mediated amyloidosis (hATTR) [30]. The success of GalNAc-conjugated siRNAs has established the liver as a prime target and spurred development for other hepatic diseases.

6.2.2 mRNA Therapeutics: Unlike ASOs and siRNAs that aim to suppress gene expression, mRNA therapeutics aim to add genetic instructions to cells, turning them into factories to produce desired therapeutic proteins. This platform involves the in vitro transcription of mRNA encoding the protein of interest, followed by chemical modifications (e.g., pseudouridine) to enhance stability and reduce innate immune recognition, and encapsulation in lipid nanoparticles (LNPs) for cellular delivery and protection from degradation [41]. The most spectacular validation of this technology came with the SARS-CoV-2 mRNA vaccines (e.g., BNT162b2, mRNA-1273). These vaccines deliver mRNA encoding the viral spike protein, leading to its transient expression in host cells, presentation to the immune system, and the generation of potent neutralizing antibodies and T-cell responses [31]. Beyond vaccines, mRNA technology has vast potential. In cancer immunotherapy, mRNAs encoding tumor-associated antigens, cytokines (e.g., interleukin-12), or chimeric antigen receptors (CARs) are being tested to stimulate anti-tumor immunity. For protein replacement therapy, mRNA offers a promising solution for monogenic disorders like cystic fibrosis or methylmalonic acidemia, where delivering a functional copy of the missing enzyme could restore metabolism. The transient nature of mRNA expression is advantageous for safety, allowing for precise dosing control without the risk of genomic integration associated with some gene therapies.

6.3 Targeting RNA structures and modifications

Moving beyond linear sequence, the complex three-dimensional folds and chemical modifications of RNA open additional avenues for pharmacological intervention. Many functional RNAs, including riboswitches, lncRNAs, and the repeat-expanded RNAs found in neurological disorders, rely on specific secondary and tertiary structures for their activity. This creates unique, druggable pockets that can be targeted by small molecules. For example, the oncogenic lncRNA MALAT1 forms a stable triple-helix structure at its 3′ end that is essential for its nuclear retention and function. Small molecules that disrupt this structure could neutralize its pro-metastatic effects [32]. Similarly, in myotonic dystrophy type 1 (DM1), expanded CUG repeats in the DMPK transcript form stable hairpins that sequester Muscleblind-like (MBNL) splicing factors. Small molecules that bind these repeat structures and disrupt the toxic RNA-protein interaction are under active investigation as potential therapies.

Simultaneously, the epitranscriptome—the collection of chemical modifications on RNA—is emerging as a rich therapeutic landscape. The enzymes that write, erase, and read these marks are druggable targets. In acute myeloid leukemia (AML), the m6A eraser FTO is often overexpressed, leading to reduced m6A levels on oncogenic transcripts like MYC and CEBPA, which enhances their stability and promotes leukemogenesis. Small-molecule inhibitors of FTO have shown promising anti-leukemic effects in preclinical models by restoring m6A levels and inducing the decay of these key oncogenes [33]. Conversely, in some contexts, inhibitors of m6A writers (e.g., METTL3) or readers (e.g., YTHDF proteins) may be beneficial. Targeting other modifications, such as pseudouridylation or adenosine-to-inosine (A-to-I) editing, also holds significant potential for modulating RNA function in disease.

7. Challenges and future directions

7.1 Technical and biological challenges

The translation of RNA biology into clinical applications, while promising, is fraught with persistent obstacles. A foundational challenge is the sheer scale of functional annotation. While projects like ENCODE and FANTOM have cataloged hundreds of thousands of non-coding RNAs, establishing their precise molecular mechanisms, in vivo functions, and causal roles in disease remains a monumental task for the vast majority. This knowledge gap hinders the identification of the most promising therapeutic targets among the ncRNA “dark matter” [42].

Perhaps the most significant translational bottleneck is tissue-specific delivery. While GalNAc-conjugation has unlocked the liver, efficient and safe delivery of RNA therapeutics to extrahepatic tissues—such as the brain (for neurodegenerative diseases), skeletal and cardiac muscle (for muscular dystrophies and heart failure), solid tumors, or specific immune cell subsets—remains a major hurdle. This requires continued innovation in delivery vehicles, including next-generation lipid nanoparticles, polymer-based carriers, and viral vectors (e.g., engineered adeno-associated viruses) tailored for specific tropisms and able to cross biological barriers like the blood-brain barrier [34].

Safety concerns also demand rigorous attention. Off-target effects can occur if an ASO or siRNA has partial complementarity to unintended RNA transcripts, leading to their unintended silencing or modulation. Immune activation is a double-edged sword; while it is desirable for vaccines, it can cause adverse inflammatory reactions for other therapeutic RNAs. Chemical modifications and sophisticated LNP formulations are used to minimize this, but balancing efficacy with immunogenicity is an ongoing design challenge. Finally, understanding the dynamic RNA-protein interactome—how networks of RNA-binding proteins (RBPs) control the fate of thousands of transcripts in a cell-state-specific manner—is crucial for predicting the systemic effects of perturbing a single RNA node and for identifying new vulnerable points in disease-associated regulatory networks [43-50].

7.2 Single-cell and spatial RNA technologies

The future of RNA research and its clinical application will be revolutionized by technologies that capture biological complexity with increasing resolution. Single-cell RNA sequencing (scRNA-seq) has already dismantled the notion of homogeneous tissues, revealing staggering cellular heterogeneity. It can identify rare, pathogenic cell populations (e.g., tumor-initiating cells, specific neuronal subtypes vulnerable in disease), trace developmental trajectories, and dissect the dynamics of cellular responses to therapy at an individual cell level [35]. This granularity is essential for understanding treatment resistance and for designing therapies that target specific pathogenic cell states.

Building on this, spatial transcriptomics technologies represent the next frontier. Methods like Visium, MERFISH, and seqFISH allow for the quantification of hundreds to thousands of RNA species while preserving their two-dimensional coordinates within a tissue section [36]. This is transformative because it adds the critical dimension of spatial context. It enables researchers to map gene expression gradients, define the molecular profiles of cells within their native tissue microenvironments (e.g., the tumor immune microenvironment), and visualize cell-cell communication circuits mediated by ligand-receptor pairs. For oncology, this could reveal how cancer cells manipulate their surroundings via secreted factors or exosomal RNAs. In neuroscience, it can chart the molecular architecture of brain regions with unprecedented detail. These technologies will be indispensable for validating that RNA therapeutics reach their intended cellular targets in situ and for understanding the spatial consequences of their action [51-65].

7.3 Integrating multi-omics and systems biology

The ultimate goal is a unified, predictive understanding of cellular systems. This will be achieved not by analyzing RNA in isolation, but through the integration of multi-omics data. Combining genomic data (genetic variants, mutations), epigenomic data (chromatin accessibility, histone marks, DNA methylation), transcriptomic data (all coding and non-coding RNAs), proteomic data (protein abundance and modifications), and metabolomic data provides a multi-layered snapshot of cellular state. For instance, integrating a tumor’s mutation profile with its chromatin accessibility landscape and RNA expression can reveal how a driver mutation rewires enhancer activity to activate a specific oncogenic lncRNA program [44].

Making sense of these colossal, multi-dimensional datasets is a task for advanced computational biology and machine learning (ML). ML models can be trained to identify complex, non-linear patterns that predict disease subtypes, prognosis, or drug response more accurately than any single data type. They can be used to reverse-engineer gene regulatory networks, inferring causal relationships between transcription factors, enhancers, and target genes. Furthermore, systems biology approaches that model the flow of information from genome to phenome will be critical for identifying key driver nodes—those RNA species or RBPs whose perturbation is predicted to have the greatest therapeutic effect with minimal systemic disruption. This integrative, model-driven approach will accelerate the transition from descriptive cataloging to mechanistic insight and robust therapeutic hypothesis generation [37].

8. Conclusion

RNA biology has decisively emerged from the shadow of DNA to claim its place at the center of molecular biology. It is the active interpreter of the genomic blueprint, a dynamic regulator of the epigenetic landscape, and a direct contributor to cellular phenotype. This review has traversed the journey from the complex genomic origins of the transcriptome, through RNA’s multifaceted roles in chromatin regulation and epitranscriptomic modification, to its critical implications in human disease and its revolutionary potential in diagnostics and therapeutics. The dysregulation of RNA processing, the mutation of RNA-binding proteins, and the aberrant expression of non-coding RNAs are unifying themes across a spectrum of pathologies, from cancer to neurodegeneration.

The convergence of high-throughput sequencing, advanced delivery technologies, and rational nucleic acid design has propelled RNA into the clinical arena. RNA biomarkers are enhancing diagnostic precision, while RNA-targeted drugs like ASOs and siRNAs, alongside mRNA vaccines, are establishing a new pharmacopeia. As we overcome challenges related to delivery, specificity, and a comprehensive understanding of RNA networks, the potential for RNA-based medicine is boundless. By continuing to explore RNA at the crossroads of genomics, epigenetics, and medicine, we are not only unraveling the fundamental logic of life but also forging powerful new tools to diagnose, monitor, and treat some of humanity’s most challenging diseases.

Author Contributions: Conceptualisation, P.K.T.; software, P.K.T.; investigation, P.K.T.;  writing—original draft preparation, P.K.T.; writing—review and editing, P.K.T.; visualisation, P.K.T.; supervision, P.K.T.; project administration, P.K.T. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to the Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague 4 Czech Republic for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. Crick F. Central dogma of molecular biology. Nature. 1970;227(5258):561-3.
  2. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
  3. Holoch D, Moazed D. RNA-mediated epigenetic regulation of gene expression. Nat Rev Genet. 2015;16(2):71-84.
  4. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell. 2009;136(4):777-93.
  5. Damase TR, et al. The Limitless Future of RNA Therapeutics. Front Bioeng Biotechnol. 2021;9:628137.
  6. Djebali S, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101-8.
  7. Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118.
  8. Li W, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature. 2013;498(7455):516-20.
  9. Rowley MJ, Corces VG. Organizational principles of 3D genome architecture. Nat Rev Genet. 2018;19(12):789-800.
  10. Wang ET, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456(7221):470-6.
  11. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321-49.
  12. Ng HH, Robert F, Young RA, Struhl K. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol Cell. 2003;11(3):709-19.
  13. Plath K, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003;300(5616):131-5.
  14. Matzke MA, Mosher RA. RNA-directed DNA methylation: an epigenetic pathway of increasing complexity. Nat Rev Genet. 2014;15(6):394-408.
  15. Tsai MC, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689-93.
  16. Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201-6.
  17. Wang X, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117-20.
  18. Batista PJ, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15(6):707-19.
  19. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-22.
  20. Gutschner T, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180-9.
  21. Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.
  22. Li Z, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 2017;31(1):127-141.
  23. Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009;37(Pt 6):1281-6.
  24. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416-38.
  25. van Rooij E, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824):575-9.
  26. Fernández-Hernando C, Suárez Y. MicroRNAs in endothelial cell homeostasis and vascular disease. Curr Opin Hematol. 2018;25(3):227-236.
  27. Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8.
  28. Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238.
  29. Finkel RS, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723-1732.
  30. Adams D, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.
  31. Pardi N, et al. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279.
  32. Disney MD, et al. Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. ACS Chem Biol. 2016;11(6):1720-8.
  33. Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019;35(4):677-691.e10.
  34. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265-280.
  35. Tang F, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377-82.
  36. Rodrigues SG, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363(6434):1463-1467.
  37. Argelaguet R, et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Mol Syst Biol. 2018;14(6):e8124.
  38. Berget SM, Moore C, Sharp PA. Spliced segments at the 5′ terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci U S A. 1977;74(8):3171-5.
  39. Brannan CI, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10(1):28-36.
  40. Calin GA, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9.
  41. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-55.
  42. Cech TR, Steitz JA. The noncoding RNA revolution—trashing old rules to forge new ones. Cell. 2014;157(1):77-94.
  43. Darnell RB. RNA protein interaction in neurons. Annu Rev Neurosci. 2013;36:243-70.
  44. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74.
  45. Fire A, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-11.
  46. He L, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-33.
  47. Iyer MK, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47(3):199-208.
  48. Jinek M, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21.
  49. Kapranov P, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316(5830):1484-8.
  50. Koren E, et al. The role of the epitranscriptome in cancer. Nat Rev Cancer. 2022;22(12):663-676.
  51. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54.
  52. Memczak S, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333-8.
  53. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155-9.
  54. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014;15(6):423-37.
  55. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430(6996):161-4.
  56. Quinodoz SA, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. Trends Cell Biol. 2014;24(11):651-63.
  57. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-66.
  58. Salmena L, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353-8.
  59. Schwanhäusser B, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337-42.
  60. Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell. 2019;179(5):1033-1055.
  61. Sontheimer EJ, Carthew RW. Silence from within: endogenous siRNAs and miRNAs. Cell. 2005;122(1):9-12.
  62. St Johnston D. The intracellular localization of messenger RNAs. Cell. 1995;81(2):161-70.
  63. Suzuki HI, et al. Regulation of microRNA biogenesis and function. Thromb Haemost. 2015;113(3):606-13.
  64. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-14.
  65. Zappulla DC, Cech TR. RNA as a flexible scaffold for proteins: yeast telomerase and beyond. Cold Spring Harb Symp Quant Biol. 2006;71:217-24.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography